Clinical Trial Update: Ambroxol as a Disease-modifying Treatment in GBA-PD [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ambroxol as a disease-modifying therapy for Parkinson disease with GBA mutation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Ambroxol (Ambroxol)

Snippet

Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | Conditions: Parkinson Disease, GBA Gene Mutation | Phase 2 | Status: COMPLETED